All News

pssfing.jpg

Predictors and Outcomes in Systemic Sclerosis

d EurekAlert!

The VEDOSS project has previously shown that 70% of patients with Raynaud’s phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on nailfold capillaroscopy –will fulfil the 2013 ACR/EULAR SSc criteria within 5 years.

Read Article
IL17

Expanding the IL-17 Therapeutic Landscape

d Adela Castro, MD

IL-17 inhibitors are an effective therapeutic for a broad spectrum of inflammatory and autoimmune diseases and its blockade has revolutionized management of diseases such as psoriasis, psoriatic arthritis and SpA. Is there a need for more medications within the same therapeutic class?

Read Article
vaccination.jpg

Safety of Recombinant Zoster Vaccine in Rheumatic Patients

d EurekAlert!

New work presented at the 2025 annual EULAR congress in Barcelona focuses on the recombinant zoster vaccine (RZV), which contains recombinant glycoprotein E – the major target of CD4+T-cells.

Read Article
lupus SLE

Social Determinants of Health in SLE

d EurekAlert!

Social determinants of health (SDH), such as socioeconomic status and educational background are factors that are increasingly recognised as critical contributors to health outcomes in chronic diseases.

Read Article
Cancer.risk_.jpg

Cancer risk in rheumatoid arthritis: anything new?

d Aurelie Najm, MD, PhD

Is there a higher risk of cancer that comes with the disease? Or with the treatments? So many confounding parameters, such as disease duration, disease state, and disease activity come into play. A promising session explored comorbidities in Rheumatoid Arthritis, in particular cancer and cardiovascular events. Here are my takeaways.

Read Article
EULAR,poster

EULAR 2025 – Day 2 Report

d Jack Cush, MD

Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options to rheumatologists. Here are a few interesting presentations from today.

Read Article
#EULAR2025 Abstr#POS0991 RCT showed Adjuvanted Herpes Zoster vaccination appeared safe in #SLE upto 1 year. However, humoral and cellular responses declined over time. Longer follow up needed to ascertain frequency of vaccine to be repeated @RheumNow https://t.co/FcUi1OfBLu

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
What kills in GCA? Greek national prospective cohort, small numbers and no doubt some channeling bias, but: Steroids (absence of DMARD use) is more of a factor than CV disease in GCA mortality. With new options, all GCA pts should be on something #EULAR2025 POS0960 @RheumNow https://t.co/Wmvf6tEvaF

Links:

David Liew drdavidliew ( View Tweet)
In PsA, can we better pick IL-17A inhibitor responders (after TNFi failure)? Transcriptomic profiling is going to get better at telling us which pathways are truly important for response to specific treatments POS0232 #EULAR2025 @RheumNow https://t.co/uycuXB0TFK

Links:

David Liew drdavidliew ( View Tweet)
KORAIL cohort Prediction model for progression of RA-ILD at 3 years A combination of classic clinical parameters incl DA , ILD pattern, ACPA KL-6 with AUC 0.75 HR=34 for progression in High risk group Need validation in an external cohort @RheumNow #EULAR2025 OP0329 https://t.co/LIvn1JCXPq

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
#digital #ulcers in #scleroderma🎯 Retrospective #iloprost vs #selexipag 👇 BIG advantage of oral #prostacyclin receptor #agonist vs iloprost healing faster ⬇️ulcers Selexipag used in iloprost failures; ⬇️IV access WOW! RCT needed #OP035 #EULAR2025 @RheumNow @eular_org https://t.co/6y9LwIlQkd

Links:

Janet Pope Janetbirdope ( View Tweet)
SLE Preview: advances to achieve deep B-cell depletion The race is on for the first chimeric antigen receptor (CAR)-based therapy to be approved for the treatment of systemic lupus erythematosus (SLE). Its main principle is to induce deep B-cell depletion, with the hope to reset https://t.co/OzQ05YFZfb
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty

Dr. John Cush RheumNow ( View Tweet)

Diagnostic delay in #SpA 🔹️Data from the @Official_ASAS Study 🔹️4339 patients 🔹️Delay was 6.6 years 🔹️Longer in axSpA and IBD-SpA, shorter in PsA and pSpA 🔹️Associated with type of initial symptoms (shorter in peripheral) POS0909 #EULAR2025 @rheumnow https://t.co/3BMYFxbKiq

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
LDCT to assess disease progression in early axSpA: -Data from SPACE cohort 67 pts (>50% male,>80% hLAB27+) - LDCT at baseline and 2 years apart. -Overall 22% pt with net disease progression. -Spine progression most frequent on thoracic spine. -Good reliability in assessing https://t.co/M2jkDusD41

Links:

Adela Castro AdelaCastro222 ( View Tweet)
🎯 Early MTX hits the mark — but only in ACPA-negative. In TREAT EARLIER, 1 year of MTX led to lasting benefits at 5 years: ➖ Less RA ➖ Better function ❌ No benefit in ACPA+ Abstract#OP0324 @RheumNow #EULAR2025

Jiha Lee JihaRheum ( View Tweet)

#ANCA #vasculitis is not created equally REVEAL cohort 588 ANCA Initial & 12 months #BVAS (activity index) mean ⬇️BVAS over 1 yr in all groups #GPA #MPA #eGPA 5yr survival not = over time ⬆️survival in eGPA & GPA vs MPA #POS0329 #EULAR2025 @RheumNow @eular_org https://t.co/cUKytqNZnS

Links:

Janet Pope Janetbirdope ( View Tweet)
#EULAR2025 Abstr#POS0325 Immunosuppressant-free is not only confined to CAR-T. Our cohort study in #SLE: 20% patients were “Super-Responder” (>3yrs response) inc. 7% IS-free after one Rituximab cycle. Non-European, APS & shorter disease duration predicted super-response @RheumNow https://t.co/nPIYpGoynR

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Is RA just one disease? No, & increasingly more efforts to subgroup RA on diff levels Simple approach - derived phenotypes map (independent of ACPA): - to broad histopath - to MTX response Omics is good, but still need to do the simple stuff better! #EULAR2025 OP0328 @RheumNow https://t.co/a8Vl7Kcjso

Links:

David Liew drdavidliew ( View Tweet)
In axSpA patients with persistent pain, digital behavioral therapy (ACT-app) improved MPI pain-related life interference (β −0.36, 95% CI −0.73 to 0.01) and affective distress (β −0.40, 95% CI −0.84 to 0.003) vs standard of care (SOC). 43% completed full program. NPS 5.8. https://t.co/T6i9jkjcoU

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×